WebDoctor Encyclopedia

Acute leukaemias Childhood

Mixed phenotype acute leukaemia (MPAL)

Mixed phenotype acute leukaemia (MPAL) is a rare acute leukaemia in which the leukaemia cells show both myeloid and lymphoid (B- or T-cell) features. It affects children and adults and is usually treated with ALL-type chemotherapy.

Medically reviewed Last reviewed October 17, 2026

What is mixed phenotype acute leukaemia?

Mixed phenotype acute leukaemia (MPAL) is a rare type of acute leukaemia in which the leukaemia cells show features of more than one type of blood cell at the same time.

Most acute leukaemias are clearly either myeloid (acute myeloid leukaemia, AML) or lymphoid (acute lymphoblastic leukaemia, ALL). In MPAL, the leukaemia cells, called blasts, carry markers of both the myeloid line and a lymphoid line, either B cells or T cells. Sometimes two separate groups of blasts are present, one of each type.

Because it does not fit neatly into either group, MPAL belongs to a family called acute leukaemias of ambiguous lineage. It accounts for about 2-5% of all acute leukaemias and affects both children and adults (Wolach and Stone, 2015; Khoury et al., 2022).

Like other acute leukaemias, MPAL develops quickly. It crowds out healthy cells in the bone marrow, leading to anaemia, infections and bleeding, and it needs urgent treatment.

1. Key facts at a glance

Feature Details
Type of disease Acute leukaemia with features of more than one blood cell line
How common About 2-5% of acute leukaemias
Who is affected Children and adults; slightly more common in males
Most common forms B/myeloid and T/myeloid
Important genetic types BCR::ABL1 (Philadelphia chromosome), KMT2A rearrangement, ZNF384 rearrangement
Key symptoms Tiredness, infections, bruising, bleeding, fever, bone pain
Main treatment Intensive chemotherapy, usually ALL-type; often a stem cell transplant in adults
Outlook Better in children (most are cured) than in adults

2. Types of MPAL

The World Health Organization (WHO) and the International Consensus Classification group MPAL by genetic changes first, then by the mix of cell lines (Khoury et al., 2022).

Type Main features
MPAL with BCR::ABL1 Has the Philadelphia chromosome; mostly adults; treated with a tyrosine kinase inhibitor plus chemotherapy
MPAL with KMT2A rearrangement Common in infants; often B/monocytic
MPAL with ZNF384 rearrangement Mostly children; usually B/myeloid
Acute leukaemia of ambiguous lineage with BCL11B rearrangement Often T/myeloid; a recently recognised group
B/myeloid MPAL, not otherwise specified Blasts show B-cell and myeloid markers
T/myeloid MPAL, not otherwise specified Blasts show T-cell and myeloid markers
Rare types For example B/T MPAL or triple lineage
Condition Difference from MPAL
Acute undifferentiated leukaemia Blasts show no clear lineage at all
AML with some lymphoid markers Mainly myeloid; does not meet MPAL criteria
ALL with some myeloid markers Mainly lymphoid; treated as ALL
Early T-cell precursor ALL Immature T-cell leukaemia; can overlap with T/myeloid MPAL

3. Causes and risk factors

The cause of MPAL is usually unknown. It develops when a very early blood-forming cell acquires genetic changes that let it grow out of control while keeping the ability to show features of several lineages (Alexander et al., 2018).

Factor Notes
Acquired gene changes Such as BCR::ABL1, KMT2A, ZNF384, PHF6 and others; these are not inherited
Previous chemotherapy or radiotherapy A small number of cases follow earlier cancer treatment
Age Infants (often KMT2A) and older adults (often BCR::ABL1)
Inherited conditions Rarely linked with conditions that raise leukaemia risk in general

MPAL is not infectious. It is not caused by anything a person did or did not do, and it is not usually passed on in families.

4. How does it look

In the blood and bone marrow

Feature What doctors see
Blood count High, normal or low white cell count; often low red cells and platelets
Blood film Blasts may be visible in the blood
Bone marrow Packed with blasts, usually more than 20% of cells
Blast appearance Some look like lymphoblasts, others like myeloblasts; sometimes two distinct groups

Under the microscope and on flow cytometry

The diagnosis rests on flow cytometry, a test that identifies proteins on and inside the blasts. Specific markers prove each lineage (Khoury et al., 2022):

Lineage Key markers
Myeloid Myeloperoxidase (MPO), or monocytic markers such as CD11c, CD14, CD64 and lysozyme
T cell Cytoplasmic CD3 at a strong level
B cell Strong CD19 with CD79a, cytoplasmic CD22 or CD10; or weaker CD19 with several of these

Visible signs

Others may notice that the person looks pale and tired, has bruises that appear easily, or has small red or purple spots on the skin called petechiae.

Some people have swollen lymph nodes in the neck, armpits or groin, or a swollen abdomen from an enlarged liver or spleen. In T/myeloid MPAL, a mass in the chest can cause swelling of the face and neck.

5. Symptoms

Symptoms usually appear over days or weeks.

Symptoms from low blood counts

Low blood count Symptoms
Low red cells (anaemia) Tiredness, weakness, pale skin, breathlessness, fast heartbeat
Low normal white cells Frequent or severe infections, fever, mouth ulcers
Low platelets Easy bruising, nosebleeds, bleeding gums, heavy periods, tiny red spots

Other symptoms

  • Fever and night sweats
  • Bone or joint pain, which is common in children
  • Loss of appetite and weight loss
  • Swollen lymph nodes
  • Fullness or pain in the left upper abdomen from an enlarged spleen
  • Breathlessness or cough if there is a mass in the chest
  • Headache, vomiting or problems with vision if the leukaemia affects the brain and spinal fluid

When to seek medical advice

See a doctor promptly for unexplained tiredness, bruising, frequent infections or bone pain that does not settle.

Seek urgent help for fever with chills, heavy bleeding, severe breathlessness, or swelling of the face and neck.

6. Diagnosis

Test Purpose
Full blood count and blood film Shows low blood counts and blasts
Bone marrow aspirate and biopsy Confirms acute leukaemia
Flow cytometry Identifies the lineage markers that define MPAL
Cytogenetics and FISH Look for the Philadelphia chromosome, KMT2A and other changes
Molecular testing (PCR or sequencing) Finds gene fusions and mutations
Lumbar puncture Checks for leukaemia in the spinal fluid
Chest X-ray or CT Looks for a mass in the chest
Clotting tests, kidney and liver tests Check general health before treatment
Tissue typing (HLA typing) Prepares for a possible stem cell transplant

MPAL diagnosis can be difficult, and samples are usually reviewed by specialist laboratories. A clear diagnosis matters because the choice of treatment depends on it.

7. Treatment

MPAL is treated in specialist leukaemia centres. Because it is rare, there are few clinical trials, and treatment is based mainly on large retrospective studies and expert consensus (Wolach and Stone, 2015; Alexander and Orgel, 2021).

Choosing the chemotherapy

Studies suggest that ALL-type chemotherapy often works as well as or better than AML-type chemotherapy for most people with MPAL, and it is usually less toxic (Matutes et al., 2011; Hrusak et al., 2018).

Treatment phase What happens
Induction Intensive chemotherapy to clear blasts from the bone marrow; usually ALL-type
Consolidation and intensification Further courses to destroy remaining leukaemia cells
CNS-directed treatment Chemotherapy into the spinal fluid to prevent or treat spread to the brain
Maintenance Lower-dose tablets and injections, often for about two years, in ALL-type schedules
Switch to AML-type treatment Considered if the leukaemia does not respond to ALL-type induction

Targeted treatment

Situation Option
BCR::ABL1 (Philadelphia-positive) A tyrosine kinase inhibitor such as imatinib, dasatinib or ponatinib added to chemotherapy
Other targetable changes Clinical trials of targeted drugs, for example menin inhibitors in KMT2A-rearranged leukaemia
Relapse or resistance Immunotherapies such as blinatumomab or CAR-T cells may be used in B/myeloid MPAL in some centres

Measuring response

Doctors measure minimal residual disease (MRD), the tiny amount of leukaemia left after treatment that cannot be seen under the microscope. MRD results help decide whether further, more intensive treatment is needed (Oberley et al., 2020).

Stem cell transplant

Group Approach
Adults An allogeneic stem cell transplant from a donor is commonly recommended in first remission
Children Transplant is usually reserved for those with persisting MRD or a poor response (Hrusak et al., 2018)

What to expect during induction

Induction usually takes about four to six weeks and is often given in hospital or with very frequent day-unit visits. A central line (a thin tube into a large vein) is usually placed so that chemotherapy can be given and blood taken without repeated needles.

During this time, blood counts fall very low. Most people need blood and platelet transfusions, and many need antibiotics for fever. A bone marrow test at the end of induction shows whether the leukaemia is in remission and measures MRD.

Older and less fit adults

Intensive treatment and transplant are not suitable for everyone. For older adults or people with other serious illnesses, doctors may suggest less intensive treatment, such as lower-dose chemotherapy, a tyrosine kinase inhibitor with steroids in BCR::ABL1-positive MPAL, or venetoclax-based combinations that are used in AML. Supportive care to control symptoms is always part of treatment.

Side effects of treatment

Side effect Notes
Infections The biggest risk during treatment
Hair loss, nausea and mouth sores Common and usually temporary
Tiredness Can last months
Fertility problems Discuss fertility preservation before treatment where possible
Graft-versus-host disease A possible complication of a donor transplant

8. Outlook (prognosis)

The outlook depends on age, genetic type and response to treatment.

Group Approximate outlook
Children treated with ALL-type therapy Most are long-term survivors, with event-free survival around 70-80% in large studies (Hrusak et al., 2018)
Adults About a third to a half are long-term survivors; in one series of 100 patients, mostly adults, 37% were alive at 5 years (Matutes et al., 2011); results are better after transplant in first remission
BCR::ABL1-positive MPAL Improved by tyrosine kinase inhibitors
KMT2A-rearranged MPAL in infants Poorer outlook
MRD-negative after induction Better outlook

Outcomes have improved as doctors have learned that ALL-type therapy suits most people with MPAL, and as targeted drugs and transplant methods have advanced.

9. Long-term effects and follow-up

After treatment, people are followed up for several years with blood tests and check-ups.

Possible late effect Follow-up
Heart problems From anthracycline drugs; heart scans
Growth and learning Monitoring in children
Fertility and hormones Hormone tests and specialist advice
Bone health From steroids; bone scans in some
Second cancers Rare; regular check-ups

Relapse

If MPAL comes back, treatment depends on the earlier treatment, the time since remission and the leukaemia’s markers at relapse. Options include different chemotherapy, immunotherapy directed at B-cell markers, targeted drugs and a stem cell transplant or second transplant. Clinical trials are especially important at this stage.

10. Living with MPAL

  • Report fever immediately; infections need urgent treatment during chemotherapy
  • Keep a thermometer at home and know your hospital’s emergency number
  • Wash hands often and avoid people with infections
  • Eat as well as possible; a dietitian can help
  • Stay as active as you feel able
  • Ask about emotional support for yourself and your family
  • Ask about school or work support during long treatment

11. Frequently asked questions

Question Answer
Is MPAL a mix of two leukaemias? Not exactly. It is one leukaemia whose cells show features of more than one blood cell line
Is MPAL treated like ALL or AML? Usually like ALL, with changes depending on response and genetic type
Will I need a stem cell transplant? Often in adults; less often in children
Is it inherited? Usually not
Can MPAL be cured? Yes, many children and a good number of adults are cured
How long does treatment take? ALL-type treatment usually lasts around two to three years including maintenance

12. Questions to ask your care team

  • What type of MPAL do I have, and which genetic changes were found?
  • Will I have ALL-type or AML-type chemotherapy?
  • What is my MRD result, and what does it mean?
  • Do you recommend a stem cell transplant?
  • Is there a targeted drug for my type of leukaemia?
  • Are there clinical trials I could join?
  • How can I protect my fertility?

Resources

  1. Alexander, T.B. et al. (2018) ‘The genetic basis and cell of origin of mixed phenotype acute leukaemia’, Nature, 562(7727), pp. 373-379.
  2. Alexander, T.B. and Orgel, E. (2021) ‘Mixed phenotype acute leukemia: current approaches to diagnosis and treatment’, Current Oncology Reports, 23(2), p. 22.
  3. Hrusak, O. et al. (2018) ‘International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia’, Blood, 132(3), pp. 264-276.
  4. Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms’, Leukemia, 36(7), pp. 1703-1719.
  5. Matutes, E. et al. (2011) ‘Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification’, Blood, 117(11), pp. 3163-3171.
  6. Oberley, M.J. et al. (2020) ‘Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study’, Leukemia, 34(7), pp. 1741-1750.
  7. Orgel, E. et al. (2020) ‘Mixed-phenotype acute leukemia: a cohort and consensus research strategy from the Children’s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force’, Cancer, 126(3), pp. 593-601.
  8. Wolach, O. and Stone, R.M. (2015) ‘How I treat mixed-phenotype acute leukemia’, Blood, 125(16), pp. 2477-2485.
  9. Wolach, O. and Stone, R.M. (2020) ‘Optimal therapeutic strategies for mixed phenotype acute leukemia’, Current Opinion in Hematology, 27(2), pp. 95-102.

Prepared by the editorial team, October 2026.